Targeted vaccination and the speed of SARS-CoV-2 adaptation
The limited supply of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises the question of targeted vaccination. Many countries have opted to vaccinate older and more sensitive hosts first to minimize the disease burden. However, what are the evolutionary consequences...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 3 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
18.01.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The limited supply of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raises the question of targeted vaccination. Many countries have opted to vaccinate older and more sensitive hosts first to minimize the disease burden. However, what are the evolutionary consequences of targeted vaccination? We clarify the consequences of different vaccination strategies through the analysis of the speed of viral adaptation measured as the rate of change of the frequency of a vaccine-adapted variant. We show that such a variant is expected to spread faster if vaccination targets individuals who are likely to be involved in a higher number of contacts. We also discuss the pros and cons of dose-sparing strategies. Because delaying the second dose increases the proportion of the population vaccinated with a single dose, this strategy can both speed up the spread of the vaccine-adapted variant and reduce the cumulative number of deaths. Hence, strategies that are most effective at slowing viral adaptation may not always be epidemiologically optimal. A careful assessment of both the epidemiological and evolutionary consequences of alternative vaccination strategies is required to determine which individuals should be vaccinated first. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 1 S.G. and S.L. contributed equally to this work. Author contributions: S.G. and S.L. designed research, performed research, and wrote the paper. Edited by Eugene Koonin, National Center for Biotechnology Information, National Library of Medicine, NIH, Bethesda, MD; received June 22, 2021; accepted November 18, 2021 |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.2110666119 |